Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Hypomethylating Agents as a Therapy for AML.

Literature DB >> 28286907

Hypomethylating Agents as a Therapy for AML.

Abstract

Acute myeloid leukemia (AML) is predominantly a disease of older adults associated with poor long-term outcomes with available therapies. Used as single agents, hypomethylating agents (HMAs) induce only 15 to 25% complete remissions, but current data suggest that median OS observed after HMAs is comparable to that observed after more intensive therapies. Whether long-term cure may be obtained in some patients treated with HMAs is unknown. Combinations of HMAs to novel agents are now extensively investigated and attractive response rates have been reported when combining HMAs to different drug classes. The absence of reliable predictive biomarkers of efficacy of HMAs in AML and the uncertainties regarding their most relevant mechanisms of action hinder the rational design of the combinations to be tested in priority, usually in untreated older AML patients.

Entities: Disease Species

Keywords: Acute myeloid leukemia; Azacitidine; Combination studies; Decitabine; Immune effects

Mesh：

Substances：

Year: 2017 PMID： 28286907 DOI： 10.1007/s11899-017-0363-4

Source DB: PubMed Journal: Curr Hematol Malig Rep ISSN： 1558-8211 Impact factor: 3.952

75 in total

1. A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML.

Authors: G Ramsingh; P Westervelt; A F Cashen; G L Uy; K Stockerl-Goldstein; C N Abboud; N Bernabe; R Monahan; J F DiPersio; R Vij
Journal: Leukemia Date: 2012-07-25 Impact factor: 11.528

2. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.

Authors: Amanda F Cashen; Gary J Schiller; Margaret R O'Donnell; John F DiPersio
Journal: J Clin Oncol Date: 2009-12-21 Impact factor: 44.544

3. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

Authors: Lewis R Silverman; David R McKenzie; Bercedis L Peterson; James F Holland; Jay T Backstrom; C L Beach; Richard A Larson
Journal: J Clin Oncol Date: 2006-08-20 Impact factor: 44.544

4. Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias.

Authors: Marcos de Lima; Farhad Ravandi; Munir Shahjahan; Borje Andersson; Daniel Couriel; Michele Donato; Issa Khouri; James Gajewski; Koen van Besien; Richard Champlin; Sergio Giralt; Hagop Kantarjian
Journal: Cancer Date: 2003-03-01 Impact factor: 6.860

5. DNMT3A mutations in acute myeloid leukemia.

Authors: Timothy J Ley; Li Ding; Matthew J Walter; Michael D McLellan; Tamara Lamprecht; David E Larson; Cyriac Kandoth; Jacqueline E Payton; Jack Baty; John Welch; Christopher C Harris; Cheryl F Lichti; R Reid Townsend; Robert S Fulton; David J Dooling; Daniel C Koboldt; Heather Schmidt; Qunyuan Zhang; John R Osborne; Ling Lin; Michelle O'Laughlin; Joshua F McMichael; Kim D Delehaunty; Sean D McGrath; Lucinda A Fulton; Vincent J Magrini; Tammi L Vickery; Jasreet Hundal; Lisa L Cook; Joshua J Conyers; Gary W Swift; Jerry P Reed; Patricia A Alldredge; Todd Wylie; Jason Walker; Joelle Kalicki; Mark A Watson; Sharon Heath; William D Shannon; Nobish Varghese; Rakesh Nagarajan; Peter Westervelt; Michael H Tomasson; Daniel C Link; Timothy A Graubert; John F DiPersio; Elaine R Mardis; Richard K Wilson
Journal: N Engl J Med Date: 2010-11-10 Impact factor: 91.245

6. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.

Authors: Andres O Soriano; Hui Yang; Stefan Faderl; Zeev Estrov; Francis Giles; Farhad Ravandi; Jorge Cortes; William G Wierda; Souzanne Ouzounian; Andres Quezada; Sherry Pierce; Elihu H Estey; Jean-Pierre J Issa; Hagop M Kantarjian; Guillermo Garcia-Manero
Journal: Blood Date: 2007-06-27 Impact factor: 22.113

7. Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG).

Authors: Heiko Becker; Stefan Suciu; Björn Hans Rüter; Uwe Platzbecker; Aristoteles Giagounidis; Dominik Selleslag; Boris Labar; Ulrich Germing; Helmut R Salih; Petra Muus; Karl-Heinz Pflüger; Anne Hagemeijer; Hans-Eckart Schaefer; Valeria Fiaccadori; Frédéric Baron; Arnold Ganser; Carlo Aul; Theo de Witte; Pierre W Wijermans; Michael Lübbert
Journal: Ann Hematol Date: 2015-09-24 Impact factor: 3.673

8. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome.

Authors: N Daver; H Kantarjian; F Ravandi; E Estey; X Wang; G Garcia-Manero; E Jabbour; M Konopleva; S O'Brien; S Verstovsek; T Kadia; C Dinardo; S Pierce; X Huang; N Pemmaraju; M Diaz-Pines-Mateo; J Cortes; G Borthakur
Journal: Leukemia Date: 2015-09-14 Impact factor: 11.528

9. Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the Study Alliance Leukemia.

Authors: C Müller-Tidow; P Tschanter; C Röllig; C Thiede; A Koschmieder; M Stelljes; S Koschmieder; M Dugas; J Gerss; T Butterfaß-Bahloul; R Wagner; M Eveslage; U Thiem; S W Krause; U Kaiser; V Kunzmann; B Steffen; R Noppeney; W Herr; C D Baldus; N Schmitz; K Götze; A Reichle; M Kaufmann; A Neubauer; K Schäfer-Eckart; M Hänel; R Peceny; N Frickhofen; M Kiehl; A Giagounidis; M Görner; R Repp; H Link; A Kiani; R Naumann; T H Brümmendorf; H Serve; G Ehninger; W E Berdel; U Krug
Journal: Leukemia Date: 2015-11-02 Impact factor: 11.528

10. Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group.

Authors: Lisa Pleyer; Sonja Burgstaller; Michael Girschikofsky; Werner Linkesch; Reinhard Stauder; Michael Pfeilstocker; Martin Schreder; Christoph Tinchon; Thamer Sliwa; Alois Lang; Wolfgang R Sperr; Peter Krippl; Dietmar Geissler; Daniela Voskova; Konstantin Schlick; Josef Thaler; Sigrid Machherndl-Spandl; Georg Theiler; Otto Eckmüllner; Richard Greil
Journal: Ann Hematol Date: 2014-06-21 Impact factor: 3.673

20 in total

1. Horizontal meta-analysis identifies common deregulated genes across AML subgroups providing a robust prognostic signature.

Authors: Ali Nehme; Hassan Dakik; Frédéric Picou; Meyling Cheok; Claude Preudhomme; Hervé Dombret; Juliette Lambert; Emmanuel Gyan; Arnaud Pigneux; Christian Récher; Marie C Béné; Fabrice Gouilleux; Kazem Zibara; Olivier Herault; Frédéric Mazurier
Journal: Blood Adv Date: 2020-10-27

Review 2. How and when to decide between epigenetic therapy and chemotherapy in patients with AML.

Authors: Hervé Dombret; Raphael Itzykson
Journal: Hematology Am Soc Hematol Educ Program Date: 2017-12-08

3. A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia.

Authors: Kirk E Cahill; Yasmin H Karimi; Theodore G Karrison; Nitin Jain; Margaret Green; Howard Weiner; Noreen Fulton; Sabah Kadri; Lucy A Godley; Andrew S Artz; Hongtao Liu; Michael J Thirman; Michelle M Le Beau; Megan E McNerney; Jeremy Segal; Richard A Larson; Wendy Stock; Olatoyosi Odenike
Journal: Blood Adv Date: 2020-02-25

10. GSK-J4 induces cell cycle arrest and apoptosis via ER stress and the synergism between GSK-J4 and decitabine in acute myeloid leukemia KG-1a cells.

Authors: Xuan Chu; Liang Zhong; Lihua Yu; Ling Xiong; Jian Li; Wenran Dan; Jiao Ye; Chen Liu; Xu Luo; Beizhong Liu
Journal: Cancer Cell Int Date: 2020-06-03 Impact factor: 5.722